TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03649269

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PC-300 tea.
Description: Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate
Description: Patients were prescribed 200 mg/day at night.
Study: NCT04677036

Intervention type: OTHER
Intervention: No intervention is given
Description: No intervention given

Intervention type: OTHER
Intervention: No intervention is given
Description: No intervention given
Study: NCT03041480

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipid levels and Lp-PLA2
Description: Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipid levels and Lp-PLA2
Description: Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipid levels and Lp-PLA2
Description: Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
Study: NCT03954873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide 2
Description: Human glucagon-like peptide 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide 2
Description: Human glucagon-like peptide 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide 2
Description: Human glucagon-like peptide 2
Study: NCT00747383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 3mg oral tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg oral tablet.
Study: NCT02956525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: Dexibuprofen 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: Dexibuprofen 200 mg
Study: NCT01970566

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and Drug
Description: Topiramate-Phentermine plus cognitive behavioral therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Intense Exercise/Moderate Calorie Restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral and Drug
Description: Topiramate-Phentermine plus cognitive behavioral therapy
Study: NCT02964611

Intervention type: BEHAVIORAL
Intervention: Observational Study
Description: This is an observational study.

Intervention type: BEHAVIORAL
Intervention: Observational Study
Description: This is an observational study.

Intervention type: BEHAVIORAL
Intervention: Observational Study
Description: This is an observational study.

Intervention type: BEHAVIORAL
Intervention: Observational Study
Description: This is an observational study.
Study: NCT01970566

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: Intense Exercise/Moderate Calorie Restriction
Study: NCT01747174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC Adenosine
Description: IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC Sodium nitroprusside (SNP)
Description: IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCI
Description: PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
Study: NCT03282331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard oxygenation
Description: Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High flow nasal oxygenation
Description: Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
Study: NCT01747174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard PCI
Description: PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard PCI
Description: PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
Study: NCT04388722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse CO-Oximeter Sensor
Description: Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
Study: NCT02404753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemotherapy
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Laparoscopic distal gastrectomy with D2 lymph node dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: Open distal gastrectomy with D2 lymph node dissection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
Study: NCT02490072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
Study: NCT03282331

Intervention type: PROCEDURE
Group type: OTHER
Intervention: noninvasive ventilation
Description: Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
Study: NCT03954873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 20% (w/v) glucose infusion for regulating plasma glucose
Study: NCT02067052

Intervention type: PROCEDURE
Intervention: Surgery, radiotherapy and chemotherapy
Description: Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy

Intervention type: PROCEDURE
Intervention: Surgery
Description: Vulvectomy \& lymphadenectomy
Study: NCT00822809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10

Intervention type: DRUG
Group type: OTHER
Intervention: Catumaxomab
Description: Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 25 mg premedication
Study: NCT04361474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal
Description: Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.
Study: NCT03320512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3
Description: P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3+
Description: In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control participants will receive the standard of care for receiving a prescription for PrEP.
Study: NCT03526640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BioSentry Tract Sealant System
Description: The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
Study: NCT01363505

Intervention type: DEVICE
Intervention: BARD® Intra-abdominal Pressure monitor
Description: monitor linked to foley catheter that is able to measure pressure inside bladder
Study: NCT03844971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer assisted arthrocentesis of
Description: Under general anesthesia : patients specific preoperative prefabricated surgical guide will be used intraoperative for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction
Study: NCT03401489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PACESETTER
Description: Patients will be given a Viaca electronic pill tray \& blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational \& reinforcement messages guided by self-determination theory constructs of competence \& autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
Study: NCT04091867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sEphB4-HSA with chemotherapy
Description: sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
Study: NCT02490072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline(Saline 0.9%)
Study: NCT00712959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)
Description: 0.5 ml, IM
Study: NCT04091867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 6930 cGy IMRT starting D15-D18
Study: NCT04468750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotape
Description: During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.
Study: NCT01154725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education and rehabilitation
Description: Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: habitual patient education
Description: habitual patient education
Study: NCT00712959

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)
Description: 0.5 mL, IM
Study: NCT03911583

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: The control group does not receive these notifications (PUSH)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate physical activity group (MPA)
Description: The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intense physical activity group (IPA)
Description: The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
Study: NCT01370083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tongue Pressure Profile Training
Description: 60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tongue-Pressure Strength-and-Accuracy Training
Description: 60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
Study: NCT03319394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The First Twenty
Description: The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
Study: NCT02043522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioisotope
Description: One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
Study: NCT02343926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMIGLIPTIN LS15-0444
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT01520792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol (drug)
Description: Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
Study: NCT03994640

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cannabis Cream
Description: Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
Study: NCT02343926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT03954873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 20% (w/v) glucose infusion for regulating plasma glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 20% (w/v) glucose infusion for regulating plasma glucose
Study: NCT03994640

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
Study: NCT03406156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered via intravenous infusion
Study: NCT03954873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 20% (w/v) glucose infusion for regulating plasma glucose
Study: NCT02769871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroimages of stroke
Description: Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
Study: NCT03954873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Actrapid (insulin) for lowering plasma glucose
Study: NCT03406156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.